Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
H Döhner, E Estey, D Grimwade… - Blood, The Journal …, 2017 - ashpublications.org
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
Recent progress in histone deacetylase inhibitors as anticancer agents
Histone Deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …
[HTML][HTML] Current approaches in the treatment of relapsed and refractory acute myeloid leukemia
NR Ramos, CC Mo, JE Karp, CS Hourigan - Journal of clinical medicine, 2015 - mdpi.com
The limited sensitivity of the historical treatment response criteria for acute myeloid leukemia
(AML) has resulted in a different paradigm for treatment compared with most other cancers …
(AML) has resulted in a different paradigm for treatment compared with most other cancers …
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review
JE Megías-Vericat, D Martínez-Cuadrón, MÁ Sanz… - Annals of …, 2018 - Springer
Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …
with no satisfactory and standard salvage chemotherapy regimen. We performed a …
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
Venetoclax, a selective B cell leukemia/lymphoma-2 (BCL2) inhibitor, has recently shown
activity in relapsed or refractory (R/R) acute myeloid leukemia (AML). Effective biomarkers …
activity in relapsed or refractory (R/R) acute myeloid leukemia (AML). Effective biomarkers …
Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
MR Savona, K Kolibaba, P Conkling… - American journal of …, 2018 - Wiley Online Library
Abstract CC‐486 (oral azacitidine) is an epigenetic modifier in clinical development for
treatment of hematological cancers. This study of extended CC‐486 dosing included …
treatment of hematological cancers. This study of extended CC‐486 dosing included …
Treatment of relapsed/refractory acute myeloid leukaemia in adults
A Rashidi, DJ Weisdorf… - British journal of …, 2018 - Wiley Online Library
The prognosis of relapsed acute myeloid leukaemia (AML) is poor and treatment is
challenging. While the most potent treatment modality for patients who achieve a complete …
challenging. While the most potent treatment modality for patients who achieve a complete …
A review of treatment options employed in relapsed/refractory AML
MZ Mohamed Jiffry, R Kloss, M Ahmed-Khan… - …, 2023 - Taylor & Francis
Introduction: Acute myeloid leukemia [AML] is a heterogenous group of primary
hematopoietic neoplasms arising from myeloid precursor cells. Up to 50% of patients failed …
hematopoietic neoplasms arising from myeloid precursor cells. Up to 50% of patients failed …
Hypomethylating agents as a therapy for AML
C Gardin, H Dombret - Current hematologic malignancy reports, 2017 - Springer
Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with
poor long-term outcomes with available therapies. Used as single agents, hypomethylating …
poor long-term outcomes with available therapies. Used as single agents, hypomethylating …
Azacitidine in adult patients with acute myeloid leukemia
AC Schuh, H Döhner, L Pleyer, JF Seymour… - Critical reviews in …, 2017 - Elsevier
Azacitidine is recommended front-line treatment for older patients with acute myeloid
leukemia (AML) who are not candidates for intensive treatment regimens, and was recently …
leukemia (AML) who are not candidates for intensive treatment regimens, and was recently …